Apr. 6, 2023 /
PRZen / HAZLET, N.J. -- In this CE Symposium, during the 2023 American Nephrology Nurses Association #ANNAnurses, expert faculty will discuss the clinical evidence that newer potassium binders and sodium-glucose cotransporter-2 (SGLT2) inhibitors can have a dramatic impact on outcomes of patients with chronic kidney disease (CKD). Potassium binders can not only effectively treat hyperkalemia, which can potentially be life-threatening, but very importantly enable CKD patients to continue taking life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Furthermore, potassium binders can prevent the need for urgent rescue therapy to reduce serum potassium in end-stage renal disease (ESRD) patients undergoing adequate dialysis. SGLT2 inhibitors have demonstrated significant reductions in the progression of CKD as well as in cardiovascular risk—in individuals with and without type 2 diabetes. It is therefore essential for nephrology nurses to not only be aware of the robust clinical data with these therapies but also play a critical role in the effective implementation of therapy, patient education, and adherence. Therefore, in this symposium, experts will interpret clinical evidence with these agents, and panel discussions will address prudent patient behaviors and fundamental knowledge for outcomes to be optimized.
Click here for more informationFACULTY
Molly Cahill, APRN, BC, NP-C, CNN
Kansas City Kidney Consultants Pa
Kansas City, Missouri
Debra Castner, RN, MSN, APN, CNN
Nephrology Nursing Consultant
Exmore, Virginia
David Cherney, MD CM, PhD, FRCP(C)
Professor of Medicine, University of Toronto
Clinician Scientist, Division of Nephrology, UHN
Director, Renal Physiology Laboratory, UHN
Senior Scientist, Toronto General Hospital Research Institute
Toronto, Ontario, Canada
Csaba P. Kovesdy, MD
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clinical Trials Program in Nephrology
University of Tennessee Health Science Center
Memphis VA Medical Center
Memphis, Tennessee
Voxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.
This educational activity is intended for nephrology nurses and other nurses and clinicians treating patients with #hyperkalemia.
American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
ANNA is a provider by the California Board of Registered Nursing, provider number CEP 00910.
Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #ANNAnurses #sglt2 #nephrology #nephrologynurse #hyperkalemia
Follow the full story here:
https://przen.com/pr/33502307